A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

NCT02671513 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: SHR6390

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]